{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:13:14Z","timestamp":1788955994870,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005758","name":"Universit\u00e0 Politecnica delle Marche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>CD38 is a type II glycoprotein highly expressed on plasmablasts and on short- and long-lived plasma cells, but weakly expressed by lymphoid, myeloid, and non-hematopoietic cells. CD38 is a target for therapies aimed at depleting antibody-producing plasma cells. Systemic sclerosis (SSc) is an immune-mediated disease with a well-documented pathogenic role of B cells. We therefore analyzed CD38 expression in different subsets of peripheral blood mononuclear cells (PBMCs) from a cohort of SSc patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cell surface expression of CD38 was evaluated on PBMCs from SSc patients using eight-color flow cytometry analysis performed with a FacsCanto II (BD). Healthy individuals were used as controls (HC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-six SSc patients (mean age 56, range 23-79 years; 38 females and 8 males), and thirty-two age- and sex-matched HC were studied. Twenty-eight patients had the limited cutaneous form and eighteen the diffuse cutaneous form of SSc. The mean disease duration was 7 years. Fourteen patients were on immunosuppressive therapy (14 MMF, 5 RTX). The total percentages of T, B and NK cells were not different between SSc and HC. Compared to HC, SSc patients had higher levels of CD3+CD38+ T cells (p&amp;lt;0.05), higher percentage (p&amp;lt;0.001) of CD3+CD4+CD25+FOXP3+ regulatory T cells, lower percentage (p&amp;lt;0.05) of CD3+CD56+ NK T cells. Moreover, SSc patients had higher levels of CD24<jats:sup>high<\/jats:sup>CD19+CD38<jats:sup>high<\/jats:sup> regulatory B cells than HC (p&amp;lt;0.01), while the amount of CD24+CD19+CD38+CD27+ memory B cells was lower (p&amp;lt;0.001). Finally, the percentages of circulating CD38<jats:sup>high<\/jats:sup>CD27+ plasmablasts and CD138+CD38<jats:sup>high<\/jats:sup> plasma cells were both higher in the SSc group than in HC (p&amp;lt;0.001). We did not observe any correlations between these immunophenotypes and disease subsets or duration, and ongoing immunosuppressive treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The increased expression of CD38 in peripheral blood plasmablasts and plasma cells of SSc patients may suggest this ectoenzyme as a candidate therapeutic target, under the hypothesis that depletion of these cells may beneficially downregulate the chronic immune response in SSc patients. Validation of this data in multicenter cohorts shall be obtained prior to clinical trials with existing anti-CD38 drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1072462","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:46:11Z","timestamp":1671608771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis"],"prefix":"10.3389","volume":"13","author":[{"given":"S.","family":"Agarbati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Benfaremo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Svegliati Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Funaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moroncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Malavasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.10.007","article-title":"Agonistic antibodies in systemic sclerosis","volume":"195","author":"Moroncini","year":"2018","journal-title":"Immunol Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European scleroderma trial and research (EUSTAR) group","volume":"74","author":"Jordan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"160","author":"Goswami","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of rituximab in systemic sclerosis: A systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05698-4","article-title":"Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis","volume":"40","author":"Moradzadeh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of b-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: an American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B11","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"B12","first-page":"3","article-title":"Role of viral infections in the etiopathogenesis of systemic sclerosis","volume":"31","author":"Moroncini","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0638-1","article-title":"The role of invariant natural killer T cells in microbial immunity","volume":"19","author":"Kinjo","year":"2013","journal-title":"J Infect Chemother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00760","article-title":"CD38 in adenosinergic pathways and metabolic re-programming in human multiple myeloma cells: In-tandem insights from basic science to therapy","volume":"10","author":"Horenstein","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: An immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/jcm8050625","article-title":"Cytometric characterization of main immunocompetent cells in patients with systemic sclerosis: Relationship with disease activity and type of immunosuppressive treatment","volume":"8","author":"Gumkowska-Sroka","year":"2019","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/cells9071716","article-title":"CD38: T cell immuno-metabolic modulator","volume":"9","author":"Kar","year":"2020","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered b lymphocyte function induces systemic autoimmunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol Immunol"},{"key":"B19","article-title":"Reduced non-switched memory b cell subsets cause imbalance in b cell repertoire in systemic sclerosis","author":"Simon","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686483","article-title":"Increased frequency of activated switched memory b cells and its association with the presence of pulmonary fibrosis in diffuse cutaneous systemic sclerosis patients","volume":"12","author":"Simon","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00496","article-title":"Systemic sclerosis patients present alterations in the expression of molecules involved in b-cell regulation","volume":"6","author":"Soto","year":"2015","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/biomedicines10010163","article-title":"Systemic sclerosis: From pathophysiology to novel therapeutic approaches","volume":"10","author":"Benfaremo","year":"2022","journal-title":"Biomedicines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.015","article-title":"Altered b lymphocyte homeostasis and functions in systemic sclerosis","volume":"17","author":"Forestier","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.938785","article-title":"Involvement of b cells in the development of systemic sclerosis","volume":"13","author":"Yoshizaki","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00053","article-title":"B cell homeostasis and functional properties are altered in an hypochlorous acid-induced murine model of systemic sclerosis","volume":"8","author":"Sanges","year":"2017","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2020.19131","article-title":"Putative functional pathogenic autoantibodies in systemic sclerosis","volume":"7","author":"Benfaremo","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103076","DOI":"10.1016\/j.isci.2021.103076","article-title":"Targeting b cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology","volume":"24","author":"Werner","year":"2021","journal-title":"iScience"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000737","article-title":"The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis","volume":"32","author":"Peclat","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1755-1536-4-8","article-title":"Ha-ras stabilization mediates pro-fibrotic signals in dermal fibroblasts","volume":"4","author":"Smaldone","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101902","DOI":"10.2139\/ssrn.3606762","article-title":"Targeting CD38-dependent NAD(+) metabolism to mitigate multiple organ fibrosis","volume":"24","author":"Shi","year":"2020","journal-title":"iScience"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac393","article-title":"Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus associated refractory cerebral vasculitis induces immune tolerance","author":"Yalcin Mutlu","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.616853","article-title":"Natural killer cells: Potential biomarkers and therapeutic target in autoimmune diseases","volume":"12","author":"Gianchecchi","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064531","article-title":"Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11977","DOI":"10.3390\/ijms222111977","article-title":"CD38 correlates with an immunosuppressive treg phenotype in lupus-prone mice","volume":"22","author":"Perez-Lara","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.900638","article-title":"The pathophysiological roles of regulatory T cells in the early phase of systemic sclerosis","volume":"13","author":"Kobayashi","year":"2022","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/cells9010228","article-title":"Roles of CD38 in the immune response to infection","volume":"9","author":"Glaria","year":"2020","journal-title":"Cells"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1072462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:46:15Z","timestamp":1671608775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1072462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2022.1072462"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1072462","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"article-number":"1072462"}}